FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 11/2024”.
The Monitor is a month-to-month printed overview of enterprise capital traits within the European Healthcare & Life Sciences sector.
As of the top of November 2024 we recognized the next present VC traits in Europe:
- Complete Healthcare & Life Sciences funding reached EUR 8,188m
- Biotech/Pharma acquired 60% of the whole funding quantity (EUR 4,893m) with oncology being the main indication (48%)
- In November, Alentis Therapeutics (Switzerland) secured the highest transaction quantity with EUR 168m, adopted by Adcendo (Denmark) with EUR 126m and Cradle (Netherlands) with EUR 68m
- Normal Atlantic (United States) is probably the most energetic investor (by deal quantity in 2024), adopted by European Innovation Council Fund (Belgium) and Forbion (Netherlands)
To entry the complete report, please click on right here.
